Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: roger m who wrote (8174)	1/4/1999 9:06:00 AM
From: Tharos	Read Replies (2) \| Respond to of 17367

Its a 3 dollar stock with hope. I can find 100's of those situations. So please do so.

To: roger m who wrote (8174)	1/5/1999 10:42:00 PM
From: Cacaito	Respond to of 17367

Centocor sepsis product was abandoned, they did not win in patent fights with Xoma, Xoma did. Centocor anti gram negative toxin antibody was not successful, they did not even went to the FDA, E5 from Xoma is in standby, it will comeback if Bpi is proven beneficial (big If). Few companies are dealing with sepsis, most products are behind Bpi, at best in phase II trial, best actual candidates are Acetil-hydrolase the PFA degrader (phase II in different trials), and Pharmos HU211 (sepsis indication out of picture, concentrating in head trauma). Centocor success was anticoagulant Reopro, and now they have an antiinflamatory for Chrom's disease. Dealing with FDA is not magic, either Xoma will have the evidence or they will not. The study design for Bpi is one of the best in the sepsis area, if not the best. Please, read phase II study in the Lancet, a very elegant design for a phase II, the phase III will leave no doubt (win or failure)the data will be clear. Even the best products for sepsis will be use in combination, nobody will abandon antibiotics.